| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Physiology and Biophysics, University of California, Irvine, California 92697
Submitted 13 August 2003 ; accepted in final form 3 September 2003
Insulin-like growth factor-I (IGF-I) has been shown to stimulate a hypertrophy response in skeletal muscles in vivo. In vitro studies have delineated two primary intracellular pathways that appear to mediate the effects of IGF-I in skeletal muscle: the Ras-ERK pathway and the phosphoinositide-3 kinase pathway. In vitro, the Ras pathway appears to regulate the mitogenic effects of IGF-I signaling, whereas the phosphoinositide-3 kinase pathway is associated with cellular differentiation. On the basis of the results from in vitro studies, we hypothesized that the coinfusion of both IGF-I and an inhibitor of the Ras pathway would result in some increase in muscle protein but an inhibition of cell proliferation. Our results show that 14 days of coinfusion of MAPK/ERK kinase inhibitor PD-098059 (PD) limited the phosphorylation of ERK and prevented IGF-I induced increases in protein (18%, P < 0.05 vs. 7%, not significant) or myofibrillar protein (23%, P < 0.01 vs. 5%, not significant). However, there were similar increases in indicators of cell proliferation (e.g., total DNA, 50 and 52%, P < 0.001) in both the IGF- and IGF+PD-infused muscles. The most notable impact on IGF-I signaling was a significant blunting of IGF-I induced increase in S6K1 phosphorylation by PD-98059 coinfusion (
5-fold, P < 0.001 vs. 3-fold, P < 0.01). These results suggest that there are interactions between the various pathways down stream of the IGF-I receptor that may behave differently in vivo than in myogenic cell lines in vitro.
insulin-like growth factor; p70 S6 kinase; cyclin D1; myogenin; insulin-like growth factor binding protein-5
This article has been cited by other articles:
|
|
 |
|
  H. Shi, C. Zeng, A. Ricome, K. M. Hannon, A. L. Grant, and D. E. Gerrard Extracellular signal-regulated kinase pathway is differentially involved in beta-agonist-induced hypertrophy in slow and fast muscles Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1681 - C1689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Fluckey, M. Knox, L. Smith, E. E. Dupont-Versteegden, D. Gaddy, P. A. Tesch, and C. A. Peterson Insulin-facilitated increase of muscle protein synthesis after resistance exercise involves a MAP kinase pathway Am J Physiol Endocrinol Metab, June 1, 2006; 290(6): E1205 - E1211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Lang, B. J. Krawiec, D. Huber, J. M. McCoy, and R. A. Frost Sepsis and inflammatory insults downregulate IGFBP-5, but not IGFBP-4, in skeletal muscle via a TNF-dependent mechanism Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2006; 290(4): R963 - R972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. J. van der Velden, R. C. J. Langen, M. C. J. M. Kelders, E. F. M. Wouters, Y. M. W. Janssen-Heininger, and A. M. W. J. Schols Inhibition of glycogen synthase kinase-3{beta} activity is sufficient to stimulate myogenic differentiation Am J Physiol Cell Physiol, February 1, 2006; 290(2): C453 - C462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. Oliver, J. Rosenberger, R. Lopez, A. Gomez, K. K. Cummings, and M. L. Fiorotto The Local Expression and Abundance of Insulin-Like Growth Factor (IGF) Binding Proteins in Skeletal Muscle Are Regulated by Age and Gender But Not Local IGF-I in Vivo Endocrinology, December 1, 2005; 146(12): 5455 - 5462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Haddad, F. Zaldivar, D. M. Cooper, and G. R. Adams IL-6-induced skeletal muscle atrophy J Appl Physiol, March 1, 2005; 98(3): 911 - 917. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
